{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:43:56Z","timestamp":1783748636530,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"crossref","award":["17K08452"],"award-info":[{"award-number":["17K08452"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00280-019-03949-5","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T19:02:23Z","timestamp":1568055743000},"page":"1097-1105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases"],"prefix":"10.1007","volume":"84","author":[{"given":"Kazuyo","family":"Shimada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ririka","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoka","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Uranishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Masuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-5522","authenticated-orcid":false,"given":"Mitsuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"key":"3949_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/jnci\/80.8.556","volume":"80","author":"M Zalupski","year":"1988","unstructured":"Zalupski M, Baker LH (1988) Ifosfamide. J Natl Cancer Inst 80:556\u2013566","journal-title":"J Natl Cancer Inst"},{"key":"3949_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00280-008-0876-6","volume":"63","author":"C Sioka","year":"2009","unstructured":"Sioka C, Kyritsis AP (2009) Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 63:761\u2013767. \n                    https:\/\/doi.org\/10.1007\/s00280-008-0876-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"3949_CR3","first-page":"820","volume":"289","author":"TM Visarius","year":"1999","unstructured":"Visarius TM, Stucki JW, Lauterburg BH (1999) Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J Pharmacol Exp Ther 289:820\u2013824","journal-title":"J Pharmacol Exp Ther"},{"key":"3949_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/01.coc.0000158439.02724.5a","volume":"28","author":"KA David","year":"2005","unstructured":"David KA, Picus J (2005) Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Oncol 28:277\u2013280","journal-title":"Am J Oncol"},{"key":"3949_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/1078155214527143","volume":"21","author":"AH Szabatura","year":"2015","unstructured":"Szabatura AH, Cirrone F, Harris C, McDonnell AM, Feng Y, Voit D, Neuberg D, Butrynski J, Fisher DC (2015) An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract 21:188\u2013193. \n                    https:\/\/doi.org\/10.1177\/1078155214527143","journal-title":"J Oncol Pharm Pract"},{"key":"3949_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jfma.2015.07.016","volume":"115","author":"Y Lo","year":"2016","unstructured":"Lo Y, Shen LJ, Chen WH, Dong YH, Wu FL (2016) Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis. J Formos Med Assoc 115:744\u2013751. \n                    https:\/\/doi.org\/10.1016\/j.jfma.2015.07.016","journal-title":"J Formos Med Assoc"},{"key":"3949_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bulcan.2016.11.007","volume":"104","author":"N Stern","year":"2017","unstructured":"Stern N, Sakji I, Defachelles AS, Lervat C, Ryckewaert T, Marliot G, Peugniez C, Deplanque D, Penel N (2017) Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients. Bull Cancer 104:208\u2013212. \n                    https:\/\/doi.org\/10.1016\/j.bulcan.2016.11.007","journal-title":"Bull Cancer"},{"key":"3949_CR8","unstructured":"Baxter Healthcare Corporation. Highlights of prescribing information. IFEX (Ifosfamide) for injection, intravenous use. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019763s017lbl.pdf\n                    \n                   Accessed 6 Aug 2019"},{"key":"3949_CR9","doi-asserted-by":"publisher","first-page":"e0182045","DOI":"10.1371\/journal.pone.0182045","volume":"12","author":"S Hasegawa","year":"2017","unstructured":"Hasegawa S, Matsui T, Hane Y, Abe J, Hatahira H, Motooka Y, Sasaoka S, Fukuda A, Naganuma M, Hirade K, Takahashi Y, Kinosada Y, Nakamura M (2017) Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database. PLoS One 12:e0182045. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0182045","journal-title":"PLoS One"},{"key":"3949_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2050312118772475","volume":"6","author":"M Naganuma","year":"2018","unstructured":"Naganuma M, Motooka Y, Sasaoka S, Hatahira H, Hasegawa S, Fukuda A, Nakao S, Shimada K, Hirade K, Mori T, Yoshimura T, Kato T, Nakamura M (2018) Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database. SAGE Open Med 6:1\u201311. \n                    https:\/\/doi.org\/10.1177\/2050312118772475","journal-title":"SAGE Open Med"},{"key":"3949_CR11","unstructured":"U. S. Food and Drug Administration. \u201cREADME.DOC\u201d file for the quarterly data extract (QDE) from the FDA adverse event reporting system (FAERS). \n                    http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm082193.htm\n                    \n                   Accessed 6 Aug 2019"},{"key":"3949_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.11613\/BM.2016.034","volume":"26","author":"F Habibzadeh","year":"2016","unstructured":"Habibzadeh F, Habibzadeh P, Yadollahie M (2016) On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Med 26:297\u2013307. \n                    https:\/\/doi.org\/10.11613\/BM.2016.034","journal-title":"Biochem Med"},{"key":"3949_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427\u2013436. \n                    https:\/\/doi.org\/10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3949_CR14","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1248\/bpb.b14-00191","volume":"38","author":"Y Suzuki","year":"2015","unstructured":"Suzuki Y, Suzuki H, Umetsu R, Uranishi H, Abe J, Nishibata Y, Sekiya Y, Miyamura N, Hara H, Tsuchiya T, Kinosada Y, Nakamura M (2015) Analysis of the interaction between clopidogrel, aspirin and proton pump inhibitors using the FDA Adverse Event Reporting System database. Biol Pharm Bull 38:680\u2013686. \n                    https:\/\/doi.org\/10.1248\/bpb.b14-00191","journal-title":"Biol Pharm Bull"},{"key":"3949_CR15","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1248\/bpb.b17-00266","volume":"40","author":"M Takeyama","year":"2017","unstructured":"Takeyama M, Sai K, Imatoh T, Segawa K, Hirasawa N, Saito Y (2017) Influence of Japanese regulatory action on denosumab-related hypocalcemia using Japanese Adverse Drug Event Report database. Biol Pharm Bull 40:1447\u20131453. \n                    https:\/\/doi.org\/10.1248\/bpb.b17-00266","journal-title":"Biol Pharm Bull"},{"key":"3949_CR16","doi-asserted-by":"publisher","first-page":"e0190102","DOI":"10.1371\/journal.pone.0190102","volume":"12","author":"J Abe","year":"2017","unstructured":"Abe J, Umetsu R, Uranishi H, Suzuki H, Nishibata Y, Kato Y, Ueda N, Sasaoka S, Hatahira H, Motooka Y, Masuta M, Nakamura M (2017) Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database. PLoS One 12:e0190102. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0190102","journal-title":"PLoS One"},{"key":"3949_CR17","unstructured":"Zhu AL, Li J, Leong TY (2003) Automated knowledge extraction for decision model construction: a data mining approach. In: AMIA Annual Symposium Proceedings, pp\u00a0758\u2013762"},{"key":"3949_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v014.i15","volume":"14","author":"M Hahsler","year":"2005","unstructured":"Hahsler M, Gr\u00fcn B, Hornik K, Buchta C (2005) A computational environment for mining association rules and frequent item sets. J Stat Softw 14:1\u201325. \n                    https:\/\/doi.org\/10.18637\/jss.v014.i15","journal-title":"J Stat Softw"},{"key":"3949_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius V (2013) Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf 36:995\u20131006. \n                    https:\/\/doi.org\/10.1007\/s40264-013-0061-7","journal-title":"Drug Saf"},{"key":"3949_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","volume":"1","author":"M Nakamura","year":"2015","unstructured":"Nakamura M, Umetsu R, Abe J, Matsui T, Ueda N, Kato Y, Sasaoka S, Tahara K, Takeuchi H, Kinosada Y (2015) Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. J Pharm Health Care Sci 1:34. \n                    https:\/\/doi.org\/10.1186\/s40780-015-0035-2","journal-title":"J Pharm Health Care Sci"},{"key":"3949_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.clon.2006.11.003","volume":"19","author":"T Ajithkumar","year":"2007","unstructured":"Ajithkumar T, Parkinson C, Shamshad F, Murray P (2007) Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 19:108\u2013114","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"3949_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/01.mjt.0000183719.84390.4d","volume":"14","author":"ES ElDesoky","year":"2007","unstructured":"ElDesoky ES (2007) Pharmacokinetic\u2013pharmacodynamic crisis in the elderly. Am J Ther 14:488\u2013498","journal-title":"Am J Ther"},{"key":"3949_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00776-009-1431-y","volume":"15","author":"T Tajino","year":"2010","unstructured":"Tajino T, Kikuchi S, Yamada H, Takeda A, Konno S (2010) Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. J Orthop Sci 15:104\u2013111. \n                    https:\/\/doi.org\/10.1007\/s00776-009-1431-y","journal-title":"J Orthop Sci"},{"key":"3949_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/00001813-200404000-00006","volume":"15","author":"C Rieger","year":"2004","unstructured":"Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X (2004) Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 15:347\u2013350","journal-title":"Anticancer Drugs"},{"key":"3949_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1078155208093930","volume":"14","author":"JE Howell","year":"2008","unstructured":"Howell JE, Szabatura AH, Hatfield Seung A, Nesbit SA (2008) Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 14:157\u2013162. \n                    https:\/\/doi.org\/10.1177\/1078155208093930","journal-title":"J Oncol Pharm Pract"},{"key":"3949_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.gynor.2013.06.002","volume":"12","author":"ML Shindorf","year":"2013","unstructured":"Shindorf ML, Manahan KJ, Geisler JP (2013) The interaction of ifosfamide and aprepitant in gynecologic malignancies. Gynecol Oncol Case Rep 12:34\u201335. \n                    https:\/\/doi.org\/10.1016\/j.gynor.2013.06.002","journal-title":"Gynecol Oncol Case Rep"},{"key":"3949_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/jpp.JPP_182_16","volume":"8","author":"PS Kataria","year":"2017","unstructured":"Kataria PS, Kendre PP, Patel AA (2017) Ifosfamide-induced encephalopathy precipitated by aprepitant: a rarely manifested side effect of drug interaction. J Pharmacol Pharmacother 8:38\u201340. \n                    https:\/\/doi.org\/10.4103\/jpp.JPP_182_16","journal-title":"J Pharmacol Pharmacother"},{"key":"3949_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219859644","author":"KL Lentz","year":"2019","unstructured":"Lentz KL, Clark SM, Ayarza M, Liu B, Morgan KP, Wind LS, Hairston A (2019) Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy. J Oncol Pharm Pract. \n                    https:\/\/doi.org\/10.1177\/1078155219859644","journal-title":"J Oncol Pharm Pract"},{"key":"3949_CR29","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1177\/1078155210385159","volume":"17","author":"A Richards","year":"2011","unstructured":"Richards A, Marshall H, McQuary A (2011) Evaluation of methylene blue, thiamine, and\/or albumin in the prevention of ifosfamide-related neurotoxicity. J Oncol Pharm Pract 17:372\u2013380. \n                    https:\/\/doi.org\/10.1177\/1078155210385159","journal-title":"J Oncol Pharm Pract"},{"key":"3949_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218808361","author":"EZ Gharaibeh","year":"2018","unstructured":"Gharaibeh EZ, Telfah M, Powers BC, Salacz ME (2018) Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy. J Oncol Pharm Pract. \n                    https:\/\/doi.org\/10.1177\/1078155218808361","journal-title":"J Oncol Pharm Pract"},{"key":"3949_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1078155209360074","volume":"16","author":"PA Bernard","year":"2010","unstructured":"Bernard PA, McCabe T, Bayliff S, Hayes D Jr (2010) Successful treatment of ifosfamide neurotoxicity with dexmedetomidine. J Oncol Pharm Pract 16:262\u2013265. \n                    https:\/\/doi.org\/10.1177\/1078155209360074","journal-title":"J Oncol Pharm Pract"},{"key":"3949_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/tkm2.1029","volume":"3","author":"Y Kato","year":"2016","unstructured":"Kato Y, Umetsu R, Hosoya N, Ueda N, Abe J, Nakayama Y, Motooka Y, Kinosada Y, Oyama M, Nakamura M (2016) Analysis of licorice-induced pseudoaldosteronism in the Japanese Adverse Drug Event Report database. Tradit Kampo Med 3:63\u201370. \n                    https:\/\/doi.org\/10.1002\/tkm2.1029","journal-title":"Tradit Kampo Med"},{"key":"3949_CR33","first-page":"265","volume-title":"Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS)","author":"E Poluzzi","year":"2012","unstructured":"Poluzzi E, Raschi E, Piccinni C, Ponti FD (2012) Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). Intech, Rijeka, pp 265\u2013302"},{"key":"3949_CR34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","volume":"24","author":"NR Hartnell","year":"2004","unstructured":"Hartnell NR, Wilson JP (2004) Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 24:743\u2013749","journal-title":"Pharmacotherapy"},{"key":"3949_CR35","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/pds.1633","volume":"17","author":"MA McAdams","year":"2008","unstructured":"McAdams MA, Governale LA, Swartz L (2008) Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect. Pharmacoepidemiol Drug Saf 17:882\u2013889. \n                    https:\/\/doi.org\/10.1002\/pds.1633","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3949_CR36","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/DDDT.S81998","volume":"9","author":"K Nomura","year":"2015","unstructured":"Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, Anzai T, Hashiguchi M, Mochizuki M (2015) Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Des Dev Ther 9:3031\u20133041. \n                    https:\/\/doi.org\/10.2147\/DDDT.S81998","journal-title":"Drug Des Dev Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03949-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03949-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03949-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T23:09:26Z","timestamp":1599520166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03949-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,9]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["3949"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03949-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,9]]},"assertion":[{"value":"29 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There are no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not sought for this study because the study was a database-related observational study without directly involving any research subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}